Table 1.
Population-based studies evaluating screening for liver fibrosis using transient elastography.
| Roulot 201124 | Koehler 201623 | Caballería 201822 | Abeysekara 202025 | |
|---|---|---|---|---|
| Country | France | Netherlands | Spain | United Kingdom |
| Population | Population-based | Population-based | Population-based | Population-based |
| Patients | ≥45 years | ≥45 years | 18-75 years | 22-26 years |
| Sample size (n) | 1,190 | 3,041 | 3,014 | 3,600 |
| Target | TE ≥8.0 kPa | TE ≥8.0 kPa | TE ≥8.0 kPa | TE ≥7.9 kPa |
| FibroScan probe used | M probe | M or XL probe a | M probe | M or XL probe a |
| Prevalence (%) | 7.5% | 5.6% | 5.8% | 2.7% |
| Independent predictors of the target | Diabetes ALT ≥40 IU/L Elevated WCb Age ≥57 years BMI ≥30 kg/m2 GGT ≥45 IU/L |
Diabetes ALT Age Current/former smoking HBs Ag or anti-HCV positive Liver steatosis Spleen size |
Type 2 diabetes AST and/or ALT >40 IU/L Elevated WCc Male sex Glucose ≥100 mg/dl Low HDL cholesterold Triglycerides ≥150 mg/dl |
Male sex Harmful alcohol use |
| Liver biopsy (n) | 27 | – | 60 | – |
| Fibrosis stage (n)e: | ||||
| 0 | 1 | – | 27 | – |
| 1 | 8 | – | 6 | – |
| 2 | 9 | – | 20 | – |
| 3 | 0 | – | 3 | – |
| 4 | 4 | – | 4 | – |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; IFG, impaired fasting glucose; WC, waist circumference.
a
According to the manufacturer recommendation.
b
Waist circumference ≥100 cm in men or ≥93 cm in women.
c
Waist circumference ≥102 cm in men or ≥88 cm in women.
d
HDL-cholesterol <40 mg/dl in men or <50 mg/dl in women.
e
according to the NASH CRN staging system, except for viral hepatitis in the Roulot study for which Metavir staging was used.